Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated ...

Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the ...

周二，Laidlaw分析师重申了对Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)的买入评级和68.00美元的目标价，维持了对该公司的乐观展望。这一背书紧随该公司宣布在脊髓性肌萎缩症 (SMA)治疗中使用更高剂量nusinersen的研究取得积极结果之后。

We recently compiled a list of the 10 Stocks with Biggest Upside Potential According to Hedge Funds. In this article, we are ...

On Thursday, Ionis Pharmaceuticals Inc (IONS) stock saw a decline, ending the day at $38.49 which represents a decrease of $-0.67 or -1.71% from the prior close of $39.16. The stock opened at $39.07 ...

While success is far from guaranteed in bio-land, with this week’s raising, Percheron has the horsepower to have a decent ...

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility. Investments in a currency other than sterling are exposed to currency exchange ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.